EPHA2 and intrahepatic cholangiocarcinoma: In this study, we established a novel anti-EphA2 mAb, Ea2Mab-7, which is the first mAb suitable for various applications, including flow cytometry (Fig. 2, Fig. 3, Fig. 4), Western blot (Fig. 5), ICC (Fig. 6), and IHC (Fig. 7).